EFFECTS OF ERYTHROPOIETIN ON THE TRANSFUSION REQUIREMENTS OF PRETERM INFANTS

促红细胞生成素对早产儿输血需求的影响

• 批准号: 6291001
• 负责人: JAMES LEMONS
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6291001
• 关键词: blood transfusion; clinical research; erythropoietin; human subject; human therapy evaluation; placebos; premature infant human

Evaluate the efficacy of Epo administration (compared to placebo) beginning in the first 4 days of life and continuing through discharge or 35 weeks post conceptual age, on the number of donor exposures, the number of transfusions and the number of nontransfused preterm infants enrolled.

评估EPO给药的功效（与安慰剂相比） 从生命的前4天开始，然后继续出院或 概念年龄35周，关于捐助者的数量，数量 输血和入学的非转移早产儿的数量。